Abstract
Albumin is a versatile drug carrier in anti-cancer drug delivery system and it also has an actively targeting capacity to tumors. Recently, nanoparticle albumin-bound (nab™) paclitaxel (nab-paclitaxel; Abraxane®) has been approved in 2006 for use in patients with metastatic breast cancer who have failed in the combination chemotherapy, and so the nab-technology has attracted much interest in the anti-cancer drug delivery system. The details about the preparation, characterization and evaluation of nab-paclitaxel (ABI-007) are discussed. The pharmacokinetics, pharmacodynamics and the clinical trials of ABI-007 are also reviewed. Furthermore, the recent applications of nabtechnology in the anti-cancer drug delivery systems are summarized by virtue of the patents pertaining to nab-technology. To sum up, nab-technology has a great potential of being applied extensively in the field of anti-cancer agents delivery in the future in order to acquire the good safety and better therapeutical effect.
Keywords: Nab- technology, anti-cancer drug, paclitaxel, albumin
Recent Patents on Anti-Cancer Drug Discovery
Title: Nanoparticle Albumin - Bound (NAB) Technology is a Promising Method for Anti-Cancer Drug Delivery
Volume: 4 Issue: 3
Author(s): Qiang Fu, Jin Sun, Wenping Zhang, Xiaofan Sui, Zhongtian Yan and Zhonggui He
Affiliation:
Keywords: Nab- technology, anti-cancer drug, paclitaxel, albumin
Abstract: Albumin is a versatile drug carrier in anti-cancer drug delivery system and it also has an actively targeting capacity to tumors. Recently, nanoparticle albumin-bound (nab™) paclitaxel (nab-paclitaxel; Abraxane®) has been approved in 2006 for use in patients with metastatic breast cancer who have failed in the combination chemotherapy, and so the nab-technology has attracted much interest in the anti-cancer drug delivery system. The details about the preparation, characterization and evaluation of nab-paclitaxel (ABI-007) are discussed. The pharmacokinetics, pharmacodynamics and the clinical trials of ABI-007 are also reviewed. Furthermore, the recent applications of nabtechnology in the anti-cancer drug delivery systems are summarized by virtue of the patents pertaining to nab-technology. To sum up, nab-technology has a great potential of being applied extensively in the field of anti-cancer agents delivery in the future in order to acquire the good safety and better therapeutical effect.
Export Options
About this article
Cite this article as:
Fu Qiang, Sun Jin, Zhang Wenping, Sui Xiaofan, Yan Zhongtian and He Zhonggui, Nanoparticle Albumin - Bound (NAB) Technology is a Promising Method for Anti-Cancer Drug Delivery, Recent Patents on Anti-Cancer Drug Discovery 2009; 4 (3) . https://dx.doi.org/10.2174/157489209789206869
DOI https://dx.doi.org/10.2174/157489209789206869 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ion Exchange Resins Transforming Drug Delivery Systems
Current Drug Delivery The Scatter Factor Signaling Pathways as Therapeutic Associated Target in Cancer Treatment
Current Medicinal Chemistry Current and Future Scenario of Immunotherapy for the Treatment of Hepatocellular Carcinoma
Current Cancer Therapy Reviews Antimicrobial Activity of Willowherb (Epilobium angustifolium L.) Leaves and Flowers
Current Drug Targets FDG-PET/CT and SPECT/CT in Oncology
Current Medical Imaging Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Current Drug Targets The Role of Emerging Genomics and Proteomics Technologies in Cancer Drug Target Discovery
Current Cancer Drug Targets Isomers of 4-[<sup>18</sup>F]fluoro-proline: Radiosynthesis, Biological Evaluation and Results in Humans Using PET
Current Radiopharmaceuticals Chemokines: Central Mediators of the Innate Response to Sepsis
Current Immunology Reviews (Discontinued) Chemoresistance in Non-Small Cell Lung Cancer
Current Medicinal Chemistry - Anti-Cancer Agents The Integral Nuclear Membrane Protein Nurim Plays a Role in the Suppression of Apoptosis
Current Molecular Medicine Melatonin Regulates Angiogenic and Inflammatory Proteins in MDA-MB-231 Cell Line and in Co-culture with Cancer-associated Fibroblasts
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member:
Current Medicinal Chemistry Hedgehog Target Genes: Mechanisms of Carcinogenesis Induced by Aberrant Hedgehog Signaling Activation
Current Molecular Medicine Phytochemicals and Antioxidants: An Evaluation in Understanding the Human Lifeline
Current Nutrition & Food Science Oxidative Stress and its Clinical Consequences: Relationship between Diabetes and Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Novel Implications for Lysophospholipids, Lysophosphatidic Acid and Sphingosine 1-Phosphate, as Drug Targets in Cancer
Anti-Cancer Agents in Medicinal Chemistry Microsomal Prostaglandin E Synthase: A Key Enzyme in PGE2 Biosynthesis and Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Quality Survival with Advanced Cervical Cancer
Current Women`s Health Reviews Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design